Rhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.82) per share and revenue of $67.6580 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.03. The firm had revenue of $60.11 million during the quarter, compared to the consensus estimate of $55.78 million. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The business’s revenue was up 83.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.81) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-3 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Up 3.9%

Shares of RYTM opened at $106.13 on Tuesday. The stock has a market capitalization of $7.27 billion, a P/E ratio of -33.91 and a beta of 1.88. Rhythm Pharmaceuticals has a twelve month low of $74.50 and a twelve month high of $122.20. The company has a 50 day moving average of $99.30 and a 200-day moving average of $95.80.

Insider Activity

In other news, Director Lynn A. Tetrault sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $100.32, for a total transaction of $3,711,840.00. Following the sale, the director owned 7,000 shares in the company, valued at $702,240. This represents a 84.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. raised its position in Rhythm Pharmaceuticals by 102.8% during the fourth quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock worth $31,165,000 after acquiring an additional 147,595 shares in the last quarter. Empowered Funds LLC grew its position in shares of Rhythm Pharmaceuticals by 94.1% in the 4th quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock valued at $446,000 after acquiring an additional 2,019 shares during the period. XTX Topco Ltd acquired a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth about $1,117,000. Wellington Management Group LLP increased its stake in shares of Rhythm Pharmaceuticals by 922.0% during the 4th quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock worth $26,777,000 after purchasing an additional 225,679 shares during the last quarter. Finally, SummitTX Capital L.P. raised its holdings in shares of Rhythm Pharmaceuticals by 580.2% in the 4th quarter. SummitTX Capital L.P. now owns 80,729 shares of the company’s stock valued at $8,641,000 after purchasing an additional 68,860 shares during the period.

Analysts Set New Price Targets

Several brokerages recently commented on RYTM. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, June 17th. Wall Street Zen raised shares of Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday. They issued an “overweight” rating and a $145.00 price target on the stock. Canaccord Genuity Group boosted their price target on shares of Rhythm Pharmaceuticals from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Finally, Citigroup restated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, June 3rd. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $138.73.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.